Dupilumab Reduces Asthma Disease Burden and Recurrent SCS Use in Patients with CRSwNP and Coexisting Asthma.

"Disclosure Mark Gurnell reports steering committee membership and speakers’ bureau fees for AstraZeneca, and speakers’ bureau fees for Novartis. Amr Radwan, Scott Nash, and Yamo Deniz are employees of Regeneron Pharmaceuticals Inc. and may hold stock and/or stock options in the company. Claus Bachert reports grants from Sanofi and was the principal investigator for studies for Sanofi, GlaxoSmithKline, and Novartis, during the conduct of the study. Njira Lugogo is an advisory board member and has received consultancy fees from Novartis, has received research grants from Avillion and Gossamer Bio, and is an advisory board member and has received consultancy fees and research grants from AstraZeneca, Genentech, GlaxoSmithKline, Regeneron Pharmaceuticals Inc., Sanofi, and Teva Pharmaceutical Industries Ltd. Seong H Cho has received grants from and is an advisory board member for Sanofi, and Regeneron, during the conduct of the study; received grants from the National Institute of Health, and received research grants from and is an advisory board member for Insmed, outside the submitted work. Haixin Zhang is a former employee of Regeneron Pharmaceuticals Inc. and may hold stock and/or stock options in the company. Asif H Khan, Juby A Jacob-Nara, and Paul J Rowe are employees of Sanofi and may hold stock and/or stock options in the company."

"Research was sponsored by Regeneron Pharmaceuticals Inc. and Sanofi. ClinicalTrials.gov identifier: NCT02912468 (SINUS-24) and NCT02898454 (SINUS-52)."